<?xml version='1.0' encoding='utf-8'?>
<document id="21264118"><sentence text="Drug-drug Interaction between Pravastatin and Gemfibrozil (Antihyperlipidemic) with Gliclazide (Antidiabetic) in Rats."><entity charOffset="30-41" id="DDI-PubMed.21264118.s1.e0" text="Pravastatin" /><entity charOffset="46-57" id="DDI-PubMed.21264118.s1.e1" text="Gemfibrozil" /><entity charOffset="59-77" id="DDI-PubMed.21264118.s1.e2" text="Antihyperlipidemic" /><entity charOffset="84-94" id="DDI-PubMed.21264118.s1.e3" text="Gliclazide" /><pair ddi="false" e1="DDI-PubMed.21264118.s1.e0" e2="DDI-PubMed.21264118.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21264118.s1.e0" e2="DDI-PubMed.21264118.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21264118.s1.e0" e2="DDI-PubMed.21264118.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21264118.s1.e0" e2="DDI-PubMed.21264118.s1.e3" /><pair ddi="false" e1="DDI-PubMed.21264118.s1.e1" e2="DDI-PubMed.21264118.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21264118.s1.e1" e2="DDI-PubMed.21264118.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21264118.s1.e1" e2="DDI-PubMed.21264118.s1.e3" /><pair ddi="false" e1="DDI-PubMed.21264118.s1.e2" e2="DDI-PubMed.21264118.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21264118.s1.e2" e2="DDI-PubMed.21264118.s1.e3" /></sentence><sentence text="Diabetes mellitus is a condition of increased blood glucose level in the body"><entity charOffset="52-59" id="DDI-PubMed.21264118.s2.e0" text="glucose" /></sentence><sentence text=" Antihyperlipidemic drugs like statins and fibrates are widely used for prophylactic treatment in dyslipideamia and atherosclerosis" /><sentence text=" Diabetic dislipidemia exists with increased triglycerides, low HDL and high LDL levels"><entity charOffset="45-58" id="DDI-PubMed.21264118.s4.e0" text="triglycerides" /></sentence><sentence text=" Hence, with oral hypoglycemic drugs, the addition of a lipid-lowering drug is necessary for controlling dislipidemia" /><sentence text=" In such a situation, there may be chances of drug-drug interactions between antidiabetic and antihyperlipidemic drugs" /><sentence text=" The present study is planned to evaluate the safety of gliclazide (antidiabetic) in the presence of pravastatin and gemfibrozil (antihyperlpidemic) in rats"><entity charOffset="56-66" id="DDI-PubMed.21264118.s7.e0" text="gliclazide" /><entity charOffset="101-112" id="DDI-PubMed.21264118.s7.e1" text="pravastatin" /><entity charOffset="117-128" id="DDI-PubMed.21264118.s7.e2" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.21264118.s7.e0" e2="DDI-PubMed.21264118.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21264118.s7.e0" e2="DDI-PubMed.21264118.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21264118.s7.e0" e2="DDI-PubMed.21264118.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21264118.s7.e1" e2="DDI-PubMed.21264118.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21264118.s7.e1" e2="DDI-PubMed.21264118.s7.e2" /></sentence><sentence text=" Studies in normal and alloxan-induced diabetic rats were conducted with oral doses of gliclazide and their combination with pravastatin and gemfibrozil, with an adequate washout period in between the treatments"><entity charOffset="23-30" id="DDI-PubMed.21264118.s8.e0" text="alloxan" /><entity charOffset="87-97" id="DDI-PubMed.21264118.s8.e1" text="gliclazide" /><entity charOffset="125-136" id="DDI-PubMed.21264118.s8.e2" text="pravastatin" /><entity charOffset="141-152" id="DDI-PubMed.21264118.s8.e3" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.21264118.s8.e0" e2="DDI-PubMed.21264118.s8.e0" /><pair ddi="false" e1="DDI-PubMed.21264118.s8.e0" e2="DDI-PubMed.21264118.s8.e1" /><pair ddi="false" e1="DDI-PubMed.21264118.s8.e0" e2="DDI-PubMed.21264118.s8.e2" /><pair ddi="false" e1="DDI-PubMed.21264118.s8.e0" e2="DDI-PubMed.21264118.s8.e3" /><pair ddi="false" e1="DDI-PubMed.21264118.s8.e1" e2="DDI-PubMed.21264118.s8.e1" /><pair ddi="false" e1="DDI-PubMed.21264118.s8.e1" e2="DDI-PubMed.21264118.s8.e2" /><pair ddi="false" e1="DDI-PubMed.21264118.s8.e1" e2="DDI-PubMed.21264118.s8.e3" /><pair ddi="false" e1="DDI-PubMed.21264118.s8.e2" e2="DDI-PubMed.21264118.s8.e2" /><pair ddi="false" e1="DDI-PubMed.21264118.s8.e2" e2="DDI-PubMed.21264118.s8.e3" /></sentence><sentence text=" Blood samples were collected in rats by retroorbital puncture at 0, 1, 2, 3, 4, 6, 8, 10 and 12 h" /><sentence text=" All the blood samples were analyzed for glucose by GOD -POD"><entity charOffset="41-48" id="DDI-PubMed.21264118.s10.e0" text="glucose" /></sentence><sentence text=" Gliclazide (Â½ TD) produced hypoglycemic activity in normal and diabetic rats, with peak activity at 2 and 8 h"><entity charOffset="1-11" id="DDI-PubMed.21264118.s11.e0" text="Gliclazide" /></sentence><sentence text=" Pravastatin (TD) + gemfibrozil (TD) combination treatment increased the hypoglycemic effect of gliclazide in normal rats or diabetic rats when administered together"><entity charOffset="1-12" id="DDI-PubMed.21264118.s12.e0" text="Pravastatin" /><entity charOffset="33-35" id="DDI-PubMed.21264118.s12.e1" text="TD" /><entity charOffset="96-106" id="DDI-PubMed.21264118.s12.e2" text="gliclazide" /><entity charOffset="14-23" id="DDI-PubMed.21264118.s12.e3" text="TD" /><pair ddi="false" e1="DDI-PubMed.21264118.s12.e0" e2="DDI-PubMed.21264118.s12.e0" /><pair ddi="false" e1="DDI-PubMed.21264118.s12.e0" e2="DDI-PubMed.21264118.s12.e3" /><pair ddi="false" e1="DDI-PubMed.21264118.s12.e0" e2="DDI-PubMed.21264118.s12.e1" /><pair ddi="false" e1="DDI-PubMed.21264118.s12.e0" e2="DDI-PubMed.21264118.s12.e2" /><pair ddi="false" e1="DDI-PubMed.21264118.s12.e3" e2="DDI-PubMed.21264118.s12.e3" /><pair ddi="false" e1="DDI-PubMed.21264118.s12.e3" e2="DDI-PubMed.21264118.s12.e1" /><pair ddi="false" e1="DDI-PubMed.21264118.s12.e3" e2="DDI-PubMed.21264118.s12.e2" /><pair ddi="false" e1="DDI-PubMed.21264118.s12.e1" e2="DDI-PubMed.21264118.s12.e1" /><pair ddi="false" e1="DDI-PubMed.21264118.s12.e1" e2="DDI-PubMed.21264118.s12.e2" /></sentence><sentence text=" The interaction observed due to inhibition of both the enzymes (CYP 450 2C9 and CYP 450 3A4) responsible for the metabolism of gliclazide showed increased half-life, which was seen in the present study"><entity charOffset="128-138" id="DDI-PubMed.21264118.s13.e0" text="gliclazide" /></sentence><sentence text=" Because concomitant administration of gliclazide with provastatin and gemfibrozil in diabetes is associated with atherosclerosis, it should be contraindicated or used with caution"><entity charOffset="39-49" id="DDI-PubMed.21264118.s14.e0" text="gliclazide" /><entity charOffset="55-66" id="DDI-PubMed.21264118.s14.e1" text="provastatin" /><entity charOffset="71-82" id="DDI-PubMed.21264118.s14.e2" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.21264118.s14.e0" e2="DDI-PubMed.21264118.s14.e0" /><pair ddi="false" e1="DDI-PubMed.21264118.s14.e0" e2="DDI-PubMed.21264118.s14.e1" /><pair ddi="false" e1="DDI-PubMed.21264118.s14.e0" e2="DDI-PubMed.21264118.s14.e2" /><pair ddi="false" e1="DDI-PubMed.21264118.s14.e1" e2="DDI-PubMed.21264118.s14.e1" /><pair ddi="false" e1="DDI-PubMed.21264118.s14.e1" e2="DDI-PubMed.21264118.s14.e2" /></sentence><sentence text="" /></document>